TABLE 4.

Phenotypic resistance after 3 days of treatment with ABT-450/r in HCV genotype 1-infected patients

ABT-450/r treatment (mg QD)	Patient	Genotype	EC50, nM		Fold change in EC50
			Baseline	After 3 days of dosing
200/100	1	1a	1.31	1.14	0.9
	2	1a	1.36	1.06	0.8
	3	1a	3.11	3.23	1.0
	4	1a	2.42	2.57	1.1
	5	1a	0.56	0.86	1.5
100/100	6	1a	1.55	10.2	6.6
	7	1b	0.04	15.5	386
	8	1a	2.80	8.84	3.2
50/100	9	1a	0.81	8.88	11
	10	1a	5.97	66.7	11
	11	1a	1.52	11.5	7.6
	12	1a	1.01	1.69	1.7
	13	1a	1.54	9.78	6.4